Abstract
Cyclodextrins are able to form host–guest complexes with hydrophobic molecules to result in the formation of inclusion complexes. The complex formation between norfloxacin form A and β-cyclodextrin was studied by exploring its structure affinity relationship in an aqueous solution and in the solid state. Kneading, freeze-drying, and physical mixture methods were employed to prepare solid complexes of norfloxacin and β-cyclodextrin. The solubility of norfloxacin significantly increased upon complexation with β-cyclodextrin as demonstrated by a solubility isotherm of the AL type along with the results of an intrinsic dissolution study. The complexes were also characterized in the solid stated by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), Fourier-transform infrared (FT-IR) spectroscopy, X-ray diffractometry, scanning electron microscopy (SEM), and solid-state nuclear magnetic resonance (ssNMR) spectrometry. The thermal analysis showed that the thermal stability of the drug is enhanced in the presence of β-cyclodextrin. Finally, the microbiological studies showed that the complexes have better potency when compared with pure drug.
Similar content being viewed by others
References
Naumann P, Dopp C. Fluoroquinolones—antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs. Internist (Berl). 1989;30:20–31.
Sárkozy G. Quinolones: a class of antimicrobial agents. Vet Med. 2001;46:257–74.
Bomma R, Naidu RAS, Yamsani MR, Veerabrahma K. Development and evaluation of gastroretentive norfloxacin floating tablets. Acta Pharm. 2009;59:211–21. doi:10.2478/v10007-009-0019-6.
Deng B, Su C, Kang Y. Determination of norfloxacin in human urine by capillary electrophoresis with electrochemiluminescence detection. Anal Bional Chem. 2006;371(385):1336–41.
United States Pharmacopeia. 35th ed. Rockville: United States Pharmacopoeial Convention, 2012.
Barbas R, Martí F, Prohens R, Puigjaner C. Polymorphism of norfloxacin: evidence of the enantiotropic relationship between polymorphs A and B. Cryst Growth Des. 2006;6:1463–67. doi:10.1021/cg060101u.
Barbas R, Prohens R, Puigjaner C. A new polymorph of norfloxacin. J Therm Anal Calorim. 2007;89:687–92.
Puigjaner C, Barbas B, Portell A, Font-Bardia M, Alcobé X, Prohens R. Revisiting of the solid state of norfloxacin. Cryst Growth Des. 2010;10:2948–53. doi:10.1021/cg9014898.
Szejtli J. Past, present, and future of cyclodextrin. Pure Appl Chem. 2004;76:1825–45.
Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech. 2005;6:329–57. doi:10.1208/pt060243.
Szejtli J. Cyclodextrins properties and applications. Drug Invest. 1990;2:11–21.
Marques HC. Applications of cyclodextrins. Rev Port Farm. 1994;44:85–96.
Ali N, Harikumar SL, Amanpreet K. Cyclodextrin: an excipient tool in drug delivery. Int Res J Pharm. 2012;3:44–50.
Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017–25.
Lee PS, Han JY, Song TW, Sung JH, Kwon OS, Song S, et al. Physicochemical characteristics and bioavailability of a novel intestinal metabolite of ginseng saponin (IH901) complexes with β-cyclodextrin. Int J Pharm. 2006;316:29–36.
Shen YL, Ying W, Yang SH, Wu LM. Determination of inclusion complex between gossypol and β-cyclodextrin. Spectrochim Acta A. 2006;65:169–72.
Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007;329:1–11.
Swanson BN, Boppana VK, Vlasses PH, Rotmensch HH, Ferguson RK. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother. 1983;23:284–88.
Ross DL, Riley CM. Aqueous solubilities of some variously substituted quinolone antimicrobials. Int J Pharm. 1990;63:237–50. doi:10.1016/0378-5173(90)90130-V.
Tripathi KD. Essentials of medical pharmacology. 40th ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 1999.
Guyot M, Fawaz F, Bildet J, Bonini F, Lagueny AM. Physicochemical characterization and dissolution of norfloxacin/cyclodextrin inclusion compounds and PEG solid dispersions. Int J Pharm. 1995;123:53–63. doi:10.1016/0378-5173(95)00039-L.
Fawaz F, Bonini F, Guyot N, Bildet J, Maury M, Lagueny AM. Bioavailability of norfloxacin from PEG 6000 solid dispersion and cyclodextrin inclusion complex in rabbits. Int J Pharm. 1996;132:271–75. doi:10.1016/0378-5173(95)04387-X.
Dua K, Ramana MV, Sara UV, Himaja M, Agrawal A, Garg V, et al. Investigation of enhancement of solubility of norfloxacin β-cyclodextrin in presence of acidic solubilizing additives. Curr Drug Deliv. 2007;4:21–5.
Chattah AK, Mroue KH, Pfund LY, Ramamoorthy A, Longhi MR, Garnero C. Insights into novel supramolecular complexes of two solid forms of norfloxacin and β-cyclodextrin. J Pharm Sci. 2013;102:3717–24. doi:10.1002/jps.23683.
Higuchi T, Connors KA. Phase-solubility techniques. Advances in analytical chemistry and instrumentation. New York: Wiley-Interscience; 1965. p. 117–212.
Harris RK. Nuclear magnetic resonance spectroscopy. London: Logman Scientific and Technical; 1994.
Khitrin AK, Fujiwara T, Akutsub H. Phase-modulated heteronuclear decoupling in NMR of solids. J Magn Reson. 2003;162:46–53. doi:10.1016/S1090-7807(02)00173-8.
Loftsson T, Hreinsdottir D, Masson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm. 2005;302:18–28. doi:10.1016/j.ijpharm.2005.05.042.
Acknowledgments
The authors are grateful to PACD-FCFAr-UNESP (Araraquara-Brazil), FAPESP process no 2010/13335-2 (São Paulo-Brazil) and CNPQ (Brasília-Brazil) for the fellowships and União Química (Minas Gerais-Brazil) for the financial support. In addition, the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), the Secretaría de Ciencia y Técnica de la Universidad Nacional de Córdoba (SECyT-UNC), and Ministerio de Ciencia y Tecnología (MinCyT) de la Provincia de Córdoba are grateful for the financial support. We also thank Ferromet S.A. (agent of Roquette in Argentina) for their donation of β-cyclodextrin. The cooperation from colleagues at the School of Pharmacy, Virginia Commonwealth University (VCU) is also highly appreciated. We also are grateful to Professor Peter R. Byron from VCU for his help and guidance with the intrinsic dissolution study.
Conflicts of Interest
The authors have declared no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chierentin, L., Garnero, C., Chattah, A.K. et al. Influence of β-cyclodextrin on the Properties of Norfloxacin Form A. AAPS PharmSciTech 16, 683–691 (2015). https://doi.org/10.1208/s12249-014-0259-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-014-0259-8